These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 23231932)

  • 21. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.
    Chen X; Zhu N; Wu Y; Zhang Y; Zhang Y; Jin K; Zhou Z; Chen G; Wang J
    Phytomedicine; 2024 Jun; 128():155317. PubMed ID: 38537439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
    Roy Choudhury S; Karmakar S; Banik NL; Ray SK
    Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
    Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
    Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
    Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
    Li N; Zhang Y; Wu T; Li M
    Ai Zheng; 2009 Aug; 28(8):838-43. PubMed ID: 19664330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
    Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
    Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL
    Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
    Kim MJ; Kim DE; Jeong IG; Choi J; Jang S; Lee JH; Ro S; Hwang JJ; Kim CS
    Anticancer Res; 2012 Aug; 32(8):3161-8. PubMed ID: 22843888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
    Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
    BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
    Wang SY; Wei YH; Shieh DB; Lin LL; Cheng SP; Wang PW; Chuang JH
    PLoS One; 2015; 10(7):e0130959. PubMed ID: 26134286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
    Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression.
    Chatterjee S; Rhee Y; Chung PS; Ge RF; Ahn JC
    J Photochem Photobiol B; 2018 Feb; 179():46-53. PubMed ID: 29331658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
    Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
    J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
    Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
    J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.